Therapy Areas: Inflammatory Diseases
Comparative Analysis of COVID-19 Reveals a Cytokine Shower, Not a Storm
20 October 2020 - - Since coronavirus disease 2019 (COVID-19) emerged, researchers and doctors have suggested that the infection provokes a destructive immune response known as a "cytokine storm" that might lead to dysfunction of the heart, kidneys, lungs, and ultimately death.

However, new research from The Feinstein Institutes for Medical Research indicates that COVID-19 does not cause cytokine storms.

The findings suggest that other factors should be examined to explain the virus' impact on organ function.

A group of scientists, including Daniel E. Leisman, MD, MSCE, and Lukas Ronner, MD, led by Clifford S. Deutschman, MS, MD, MCCM, a professor in the Institute of Molecular Medicine at the Feinstein Institutes, recently published their findings in The Lancet Respiratory Medicine.

The study, which analyzed data from 25 research studies between November 1, 2019 and April 14, 2020, revealed that cytokine levels in both severely and critically ill COVID-19 patients were profoundly lower than what was observed in other inflammatory syndromes.

The results suggest a potential alternate course of treatments as many clinicians have regularly prescribed anti-cytokine therapies to treat COVID-19.

The data pool compared cytokine and other inflammatory mediator levels in patients facing a variety of immunocompromised diseases, including 1,245 patients with severe and critical COVID-19; 2,767 patients with acute respiratory distress syndrome; 5,320 patients with sepsis, and most importantly; and 72 patients with the cytokine-release syndrome caused by cancer treatment with activated immune cells the quintessential clinical example of cytokine storm.

The results show the cytokine response in ARDS was 12-fold higher than what was seen in those with COVID-19, compared to 25 times higher with sepsis and 85 times higher with CRS.

The findings suggest clinicians should exercise restraint in administering anti-cytokine therapies for COVID-19 until randomized evidence is available.

The research was conducted in collaboration with researchers and doctors from the Icahn School of Medicine at Mount Sinai, the University of California, San Francisco School of Medicine, the Fred Hutchinson Cancer Research Center, and the Perelman School of Medicine at the University of Pennsylvania.

The Feinstein Institutes for Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State.

Home to 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine.
Login
Username:

Password:


Related Headlines